Floatz logo

Gnrh

Prostate

Memorial Sloan Kettering Cancer Centerprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Prostate cohort.

Asset / SponsorPhaseRating
DINITROGEN MONOXIDE
Beth Israel Deaconess Medical Center
Phase 4BB
Oxygen
Beth Israel Deaconess Medical Center
Phase 4BB
Epoetin Alfa
Janssen-Ortho Inc., Canada
Phase 3B
Nivolumab
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2B
Casodex
Memorial Sloan Kettering Cancer Center
Phase 2B

View all 27 →

Same molecule, other indications

Gnrh is also rated in:

cognitive disorderDormant
B
Indicative ·
57 / 100
View asset →
Down syndromeDormant
B
Indicative ·
57 / 100
View asset →
olfactory nerve disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →